| P50 | author | Christian Rolfo | Q51069805 |
| | Francesco Silvestris | Q53073679 |
| P2093 | author name string | Antonio Russo | |
| | Giuseppe Bronte | |
| | Luis E Raez | |
| | Kostantinos Papadimitriou | |
| | Noemí Reguart | |
| | Rosario García Campelo | |
| P2860 | cites work | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | The role of RANK-ligand inhibition in cancer: the story of denosumab | Q24633284 |
| | Microenvironmental regulation of metastasis | Q29547660 |
| | Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 |
| | Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production | Q31805202 |
| | Mechanisms of bone metastasis | Q33977526 |
| | Clinical course and prognostic factors following bone recurrence from breast cancer | Q34065927 |
| | Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. | Q34381979 |
| | Malignant bone pain: pathophysiology and treatment | Q34418896 |
| | Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 |
| | Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 |
| | The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors | Q34617864 |
| | American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer | Q34638008 |
| | Cancer Pain | Q35581638 |
| | Radiopharmaceuticals for palliation of painful osseous metastases | Q35865067 |
| | Bisphosphonates: preclinical review | Q35905959 |
| | The role of bisphosphonates in hormone-refractory prostate cancer | Q36017885 |
| | The clinical course of bone metastases from breast cancer | Q36027636 |
| | Targeting of therapeutic agents to bone to treat metastatic cancer | Q36117594 |
| | Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials | Q36185670 |
| | Fully human therapeutic monoclonal antibodies | Q36347397 |
| | Targeted and systemic radiotherapy in the treatment of bone metastasis | Q36679453 |
| | Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. | Q37366851 |
| | Do RANKL inhibitors (denosumab) affect inflammation and immunity? | Q37767159 |
| | Dosing of zoledronic acid throughout the treatment continuum in breast cancer. | Q37789518 |
| | Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives | Q37844292 |
| | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease | Q37847335 |
| | Consensus on the utility of bone markers in the malignant bone disease setting | Q37853723 |
| | Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease | Q37867822 |
| | Denosumab for the management of bone disease in patients with solid tumors | Q37970800 |
| | The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group | Q39562742 |
| | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 |
| | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 |
| | The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 |
| | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group | Q44978609 |
| | Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy | Q46212689 |
| | Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 |
| | Gabapentin for breakthrough pain due to bone metastases. | Q46549450 |
| | Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 |
| | SEOM guidelines for the treatment of bone metastases from solid tumours. | Q51352205 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15-26 | |
| P577 | publication date | 2013-10-28 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor | |
| P478 | volume | 14 | |